[Stock idea]: Windlas Biotech — 13 quarters in a row of record growth
While most of the market was distracted by largecap pharma names, a smaller CDMO player quietly delivered its 13th consecutive quarter of record revenue. No new drug launch. No big acquisition. Just consistent execution, disciplined capital allocation, and margins that keep inching up. Here’s what caught our eye, but before that: Help us grow: If you think our stock recommendations could add value to your friends, relatives, or acquaintances, we’d appreciate you spreading the word about Katalyst Wealth. Latest Stock recommendations…